ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2019
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Disseminated intravascular coagulation in chimeric antigen receptor T-cell therapy: a 6-year nationwide analysis of clinical outcomes and health care resource utilization in patients with hematologic malignancies.Research and practice in thrombosis and haemostasis · 2026Article
- CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders.Journal of neuroinflammation · 2025Review
- Management of adverse reactions to targeted therapy and immunotherapy for pancreatic cancer: A literature review.The Journal of international medical research · 2025Review
- Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada.Current oncology (Toronto, Ont.) · 2024Article
- [The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases.Frontiers in medicine · 2024Review
- Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.Hematology/oncology clinics of North America · 2023Review
- Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID.Archives of microbiology · 2023Review
- [Research advances on severe burn infection and cytokine storm].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Review
- The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.Frontiers in immunology · 2023Review
- Cancer Immunotherapies: What the Perioperative Physician Needs to Know.Current oncology reports · 2022Review
- Exosomes: A potential tool for immunotherapy of ovarian cancer.Frontiers in immunology · 2022Review
- Chimeric antigen receptor T cells applied to solid tumors.Frontiers in immunology · 2022Review
- Improving CAR T-Cell Persistence.International journal of molecular sciences · 2021Review
- Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital.World journal of critical care medicine · 2021Article
- Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab.Journal for immunotherapy of cancer · 2021Article
- Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges.World journal of gastroenterology · 2021Review
- The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy.Proceedings. Biological sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has proven to be a very effective cancer immunotherapy. Axicabtagene ciloleucel and tisagenlecleucel are the first-in-class anti-CD19 CAR-T currently available for relapsed/refractory adult large B-cell lymphoma. Tisagenlecleucel is also available for pediatric and young adult (up to age 25 years) patients with relapsed/refractory B-acute lymphoblastic leukemia. Cytokine release syndrome (CRS) and CAR-T-associated encephalopathy syndrome (neurotoxicity) are the most common adverse effects associated with CAR-T therapy. They can lead to significant morbidity and preclude widespread use of this treatment modality. Treatment-related deaths from severe CRS and cerebral edema have been reported. There is a significant heterogeneity in the side-effect profile of different CAR-T products under investigation and there is a need to develop standardized guidelines for toxicity grading and management. Here, we summarize the current literature on pathogenesis, clinical presentation, and management of CRS and neurotoxicity. The different grading systems of CRS and management protocols used in different trials have made it difficult to compare the outcomes of different CAR-T therapies. Several prevention strategies such as predictive biomarkers of CRS and neurotoxicity and modified CAR-T with 'built-in' safety mechanisms are being studied, with the potential to greatly expand the safety and applicability of CAR-T treatment across various malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.